Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
Vanzacaftor-tezacaftor-deutivacaftor 用于治疗 6-11 岁囊性纤维化患儿(RIDGELINE 试验 VX21-121-105):一项单臂 3 期试验的分析
期刊:Lancet Respiratory Medicine
影响因子:32.8
doi:10.1016/S2213-2600(24)00407-7
Hoppe, Jordana E; Kasi, Ajay S; Pittman, Jessica E; Jensen, Renee; Thia, Lena P; Robinson, Philip; Tirakitsoontorn, Pornchai; Ramsey, Bonnie; Mall, Marcus A; Taylor-Cousar, Jennifer L; McKone, Edward F; Tullis, Elizabeth; Salinas, Danieli B; Zhu, Jiaqiang; Chen, Yih-Chieh; Rodriguez-Romero, Violeta; Sosnay, Patrick R; Davies, Gwyneth